Geode Capital Management LLC Has $2.39 Million Position in Rezolute, Inc. (NASDAQ:RZLT)

Geode Capital Management LLC raised its position in Rezolute, Inc. (NASDAQ:RZLT) by 39.0% in the 3rd quarter, Holdings Channel reports. The firm owned 491,601 shares of the company’s stock after buying an additional 137,905 shares during the period. Geode Capital Management LLC’s holdings in Rezolute were worth $2,385,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. MML Investors Services LLC acquired a new position in shares of Rezolute in the 3rd quarter valued at $57,000. State Street Corp increased its holdings in shares of Rezolute by 11.6% in the third quarter. State Street Corp now owns 125,472 shares of the company’s stock worth $609,000 after acquiring an additional 13,000 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Rezolute during the third quarter worth about $65,000. XTX Topco Ltd raised its position in shares of Rezolute by 205.8% during the second quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock worth $145,000 after purchasing an additional 22,660 shares during the period. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Rezolute by 366.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock valued at $233,000 after purchasing an additional 42,597 shares in the last quarter. 82.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on RZLT shares. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of Rezolute in a report on Friday, November 8th. BTIG Research raised their price objective on shares of Rezolute from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, September 10th. Wedbush reaffirmed an “outperform” rating and issued a $112.00 target price on shares of Rezolute in a research note on Monday, November 4th. Finally, JMP Securities reiterated a “market outperform” rating and set a $7.00 target price on shares of Rezolute in a report on Friday, September 20th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $24.13.

Insider Activity

In related news, CFO Daron Evans acquired 10,000 shares of the business’s stock in a transaction dated Wednesday, December 18th. The stock was bought at an average price of $4.29 per share, with a total value of $42,900.00. Following the acquisition, the chief financial officer now owns 150,900 shares in the company, valued at $647,361. This represents a 7.10 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 18.39% of the stock is owned by corporate insiders.

Rezolute Trading Up 4.2 %

Rezolute stock opened at $5.43 on Wednesday. The company has a fifty day simple moving average of $5.05 and a 200 day simple moving average of $4.80. Rezolute, Inc. has a 1-year low of $0.90 and a 1-year high of $6.19. The company has a market cap of $314.63 million, a P/E ratio of -4.28 and a beta of 1.08.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.